Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial

Eur Urol. 1994;26(2):137-40. doi: 10.1159/000475363.


A total of 112 patients with recurrent lower urinary tract infection (UTI) completed the 6-month period of the trial. Patients were treated for 3 months, under double-blind conditions, with one capsule daily of either Uro-Vaxom (UV) or placebo, together with an antibiotic or chemotherapeutic agent when necessary, and observed for a further 3 months. During the 6 months of the trial a significant decrease in the number of recurrences (p < 0.0005) was noted in the UV group as compared to the placebo group. A total of 67.2% of the patients had no recurrences (p < 0.0005). The incidence of bacteriuria (germs > or = 10(5)/ml), dysuria and leukocyturia was significantly reduced. UV was well tolerated, no side effects were recorded during the trial. The drug is a useful adjuvant for the management of UTIs and for the prevention of recurrences.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Infective Agents, Urinary / therapeutic use
  • Double-Blind Method
  • Escherichia coli
  • Female
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Time Factors
  • Urinary Tract Infections / drug therapy*


  • Adjuvants, Immunologic
  • Anti-Infective Agents, Urinary